[1] |
Munroe ME,Vista ES,Merrill JT,et al.Pathways of impending disease flare in African-American systemic lupus erythematosus patients[J].J Autoimmun,2017,78:70-78.
|
[6] |
Knight CL,Nelson-Piercy C.Management of systemic lupus erythematosus during pregnancy:challenges and solutions[J].Open Access Rheumatol,2017,9:37-53.
|
[2] |
Buyon J,Kim M,Guerra M,et al.De NovoKidney Outcomes and Risk Factors for Nephritis (Flare)in a Multiethnic Cohort of Pregnant Patients with Lupus[J].Clin J Am Soc Nephrol,2017,12(6):940-946.
|
[3] |
Chen Y,Chang J,Lai E,et al.Maternal and perinatal outcomes of pregnancies in systemic lupus erythematosus:A nationwide population-based study[J].Semin Arthritis Rheum,2020,50(3):451-457.
|
[4] |
Yousef Yengej FA,van Royen-Kerkhof A,Derksen R,et al.The development of offspring from mothers with systemic lupus erythematosus.A systematic review[J].Autoimmun Rev,2017,16(7):701-711.
|
[5] |
Buyon JP,Kalunian KC,Ramsey-Goldman R,et al.Assessing disease activity in SLE patients during pregnancy[J].Lupus,1999,8(8):677-684.
|
[7] |
Ostensen M.Disease specific problems related to drug therapy in pregnancy[J].Lupus,2004,13(9):746-50.
|
[8] |
Hayslett JP.Maternal and fetal complications in pregnant women with systemic lupus erythematosus[J].Am J Kidney Dis,1991,17(2):123-126.
|
[9] |
Clowse ME,Magder LS,Witter F,et al.The impact of increased lupus activity on obstetric outcomes[J].Arthritis Rheum,2005,52(2):514-521.
|
[10] |
Deguchi M,Maesawa Y,Kubota S,et al.Factors associated with adverse pregnancy outcomes in women with systematic lupus erythematosus[J].J Reprod Immunol,2018,125:39-44.
|
[11] |
Zusman EZ,Sayre EC,Avia-Zubieta JA,et al.Patterns of medication use before,during an d after pregnancy in women with systemic lupus erythematosus:a populationbased cohort study[J].Lupus,2019,28(10):1205-1213.
|
[12] |
Smyth A,Oliveira GH,Lahr BD,et al.A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis[J].Clin J Am Soc Nephrol,2010,5(11):2060-2068.
|
[13] |
Clowse ME,Jamison M,Myers E,et al.A national study of the complications of lupus in pregnancy[J].Am J Obstet Gynecol,2008,199(2):127 e1-e6.
|
[14] |
Yang H,Liu H,Xu D,et al.Pregnancy-related systemic lupus erythematosus:clinical features,outcome and risk factors of disease flares a case control study[J].PLoS One,2014,9(8):e104375.
|
[15] |
Clark CA,Spitzer KA,Laskin CA.Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period[J].J Rheumatol,2005,32(9):1709-1712.
|
[16] |
Marx-Deseure A,Labreuche J,Launay D,et al.Are pregnancies with lupus but without APS of good prognosis?[J].Autoimmun Rev,2020,19(4):102 489.
|
[17] |
Lazzaroni MG,Dall′Ara F,Fredi M,et al.A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus[J].J Autoimmun,2016,74:106-117.
|
[18] |
Levy R,Briggs L,Silverman E,et al.Cutaneous sequelae in neonatal lupus: A retrospective cohort study[J].J Am Acad Dermato,2020,83(2):440-446.
|
[19] |
Brucato A,Cimaz R,Caporali R,et al.Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies[J].Clin Rev Allergy Immunol,2011,40(1):27-41.
|
[20] |
Jordan N.Management of pregnancy in systemic lupus erythematosus:What a GP should know[J].Lupus,2018,27(1):40-43.
|
[21] |
Izmirly P,Saxena A,Buyon JP.Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus[J].Curr Opin Rheumatol,2017,29(5):467-472.
|
[22] |
Izmirly PM,Saxena A,Kim MY,et al.Maternal and fetal factors associated with mortality and morbidity in a multiracial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus[J].Circulation,2011,124(18):1927-1935.
|
[23] |
Jaeggi E,Laskin C,Hamilton R,et al.The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants[J].J Am Coll Cardiol,2010,55(24):2778-2784.
|
[24] |
Limaye MA,Buyon JP,Cuneo BF,et al.A review of fetal and neonatal consequences of maternal systemic lupus erythematosus[J].Prenat Diagn,2020,40(9):1066-1076.
|
[25] |
Mekinian A,Lachassinn e E,Nicaise-Roland,et al.European registry of babies born to mothers with antiphospholipid syndrome[J].Ann Rheum Dis,2013,72(2):217-222.
|
[26] |
Nalli C,Iodice A,Andreo li L,et al.The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes[J].Lupus,2014,23(6):507-517.
|
[27] |
Chen HL,Shen LJ,Hsu PN,et al.Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus:Findings from a 12-year Longitudinal Study[J].J Rheumatol,2018,45(1):83-89.
|
[32] |
Paizis K.Immunomodulatory drugs in pregnancy and lactation[J].Australian Prescriber,2019,42(3):97-101.
|
[36] |
Noviani M,Wasserman S,Clowse MEB.Breastfeeding in mothers with systemic lupus erythematosus[J].Lupus,2016,25(9):973-979.
|
[28] |
Seo MR,Chae J,Kim YM,et al.Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia[J].Lupus,2019,28(6):722-730.
|
[29] |
Carina GS,Maria H,Angela T,et al.The EULAR points to consider for use of antirheumatic drugs before pregnancy,and during pregnancy and lactation[J].Ann Rheum Dis,2016,75(5):795-810.
|
[30] |
Peterson E,Lynton J,Bernard A,et al.Rheumatologic Medication Use During Pregnancy[J].Obstetrics gynecology,2020,135(5):1161-1176.
|
[31] |
Ruiz-Irastorza G,Khamashta MA.Lupus and pregnancy:integrating clues from the bench and bedside[J].J.Clin.Investig,2011,41(6):672-678.
|
[33] |
Askie LM,Duley L,Henderson-Smart DJ,et al.Antiplatelet agents for prevention of pre-eclampsia:a meta-analysis of individual patient data[J].Lancet,2007,369(9575):1791-1798.
|
[34] |
Andreoli L,Bertsias GK,Agmon-Levin N,et al.EULAR recommendations for women′s health and the management of family planning,assisted reproduction,pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome[J].Ann Rheum Dis,2017,76(3):476-485.
|
[35] |
Fanouriakis A,Kostopoulou M,Alunno A,et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J].Ann Rheum Dis,2019,78(6):736-745.
|
[37] |
Ostensen M,Khamashta M,Lockshin M,et al.Anti-inflammatory and immunosuppressive drugs and reproduction[J].Arthritis Res Ther,2006,8(3):209.
|
[38] |
Rebelo R,Pignaton E,Valeria Bahamondes M,et al.Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome:users of the 52-mg levonorgestrel-releasing intrauterine system[J].Arch Gynecol Obstet,2019,299(6):1597-1605.
|
[39] |
Mendel A,Bernatsky S,Pineau C,et al.Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen[J].Rheumatology,2019,58(7):1259-1267.
|